Multiscale Cancer Modelling and In Silico Medicine (MSCM & ISM)

PROPOSED BY

Georgios Stamatakos Research Professor, ICCS-NTUA

APPROVED TO BE TAUGHT BY THE PROPOSER IN

The School of Electrical and Computer Engineering (SECE), National Technical University of Athens (NTUA) starting in October 2014

BASIC TEXTBOOK

Multiscale Cancer Modeling, T. Deisboeck and G. Stamatakos Eds, CRC Press, Boca Raton, FL , USA, 2011. <u>http://www.crcnetbase.com/isbn/9781439814420</u> - to be denoted as "TEXTBOOK"

ADDITIONAL MATERIAL

VPH2012 – Integrative Approaches to Computational Biomedicine

(Proceedings of the Virtual Physiological Human Conference, London 2012) – to be denoted as "PROCEEDINGS"

CONTENTS

CHAPTER	CHAPTER TITLE	CONTENTS	REFERENCES TO THE TEXBOOK
NUMBER			AND OTHER INDICATIVE
			SOURCES
1.	Introduction to Multi- scale Disease	Definitions. Clinical, scientific and technological	PROCEEDINGS TEXTBOOK - Preface
	Modelling (MSDM) and I <i>n Silico</i> Medicine	framework. Necessity and prospects of MSDM / MSCM	PAPER A
	(<i>IS</i> M)	and <i>ISM/ISO</i> . Historical aspects. Importance of the	[G. Stamatakos, D. Dionysiou, A. Lunzer, R. Belleman, E. Kolokotroni, E.
	The paradigm of Multi-scale Cancer Modelling (MSCM)	subject for the electrical and computer engineer. Contents outline.	Georgiadi, M. Erdt, J. Pukacki, S. Rueping, S.Giatili, A. d' Onofrio, S. Sfakianakis, K. Marias, Ch. Desmedt, M. Tsiknakis and N. Graf, "The
	and In Silico Oncology (ISO)		Technologically Integrated Oncosimulator: Combining multiscale cancer modeling with information
			technology in the <i>in silico</i> oncology context," IEEE J. Biomedical and Health Informatics (retitled from the

	Technology in Biomedicine) Vol. 18, No. 3, May 2014, pp. 840-854. DOI: 10.1109/JBHI.2013.2284276
2. /SM//SO: Fundamental science aspects Fundamental science aspects Fundamental science aspects Fundamental science aspects Fundamental science aspects Fundamental science aspects Fundamental science adjump" principle. Basic categories of normal physiology and disease models. Classes of mathematical methods (discrete/continuous, deterministic/stochastic, mechanistic/machine learning etc.) Examples of tumour classes and types to be addressed (non small cell lung cancer, breast cancer, glioblastoma multiforme, nephroblastoma, cervix cancer, acute lymphoblastic leukemia.) Patient individualized treatment optimization through experimentation <i>in silico</i> (i.e. on the computer.) The Oncosimulator. Multidimensional spaces. The hypermatrix of the anatomic region of interest. Operators of basic biological mechanisms. Use of discrete mathematics concepts and tools (finite state machines, cellular automata, Monte Carlo technique, cell clustering into equivalence classes, dedicated algorithms etc.) Discrete Entity – Discrete Event Simulation.	TEXTBOOK - Chapter 18 PAPER_B [G. Stamatakos, E. Kolokotroni, D. Dionysiou, E. Georgiadi, C. Desmedt, "An advanced discrete state-discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study," Journal of Theoretical Biology 266 (2010) 124–13] PROCEEDINGS

		Use of continuous	
		mathematics concepts and	
		tools (ordinary differential	
		equations, partial differential	
		equations, integral	
		equations etc.) Four	
		dimensional multiscale	
		simulation of tumour growth	
		<i>in vivo</i> . Four dimensional	
		multiscale simulation of the	
		response of solid malignant	
		tumours to classical	
		therapeutic modalities	
		(chemotherapy, external	
		radiation therapy,	
		brachytherapy) <i>in vivo</i> .	
		Computer simulation of the	
		development of leukemias	
		and their response to	
		therapeutic modalities.	
		Computer simulation of the	
		response of malignant	
		tumours to new/targeted	
		therapeutic methods	
		(immunotherapy,	
		antiangiogenetic treatment	
		etc.) Computer simulation of	
		normal tissuesto treatment	
		modalities. Development of	
		semantic metamodels and	
		hypermodels in the cancer	
		and <i>in silico</i> oncology	
		domains.	
		Analogies with and	
		extensions to other diseases	
		in the generic <i>IS</i> M context.	
3.	ISM/ISO:	Architecture of the	TEXTBOOK - Chapter 18
	Technological aspects	technologically integrated	
		Oncosimulator. Workflow	PAPER_A (see above)
		design systems. High	PROCEEDINGS
		performance computer	
		systems and platforms.	
		Automated scenarios for	
		biosimulation execution.	
		Preprocessing of multiscale	

4.	<i>ISI/IS</i> O: Clinical requirements and clinical application aspects	data (imaging, histological, molecular, clinical, treatment schedule data etc.) Anonymization and pseudonymization of clinical data. Ethical and legal aspects and related technologies. Repositories of multiscale clinical data, models and model predictions. Visualization of the multiscale predictions of the Oncosimulator. Systems for the analysis of the predictions and the behaviour of the Oncosimulator. Oncosimulator. Oncosimulator integrative technologies. Portals. Analogies with and extensions to other diseases in the generic <i>ISM</i> context. Clinical questions as drivers for the Oncosimulator development. Principles and processes for the clinical adaptation and validation of Oncosimulators. Clinical	TEXTBOOK - Chapter 19 PROCEEDINGS
		extensions to other diseases	
4.	ISI/ISO: Clinical		TEXTBOOK - Chapter 19
	-	•	
			PROCEEDINGS
		•	
1			
1			
		trials as sources of multiscale	
		trials as sources of multiscale	
		trials as sources of multiscale data for the clinical	
		trials as sources of multiscale data for the clinical adaptation and validation of	
		trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the	
		trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale	
		trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators	
		trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice.	
		trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice. Analogies with and	
		trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice. Analogies with and extensions to other diseases	
	Mathematical model	trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice. Analogies with and extensions to other diseases in the generic <i>ISM</i> context.	TEYTROOK - Chapter 16
5.	Mathematical model	trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice. Analogies with and extensions to other diseases in the generic <i>ISM</i> context. The case of glioma (including	TEXTBOOK - Chapter 16
5.	formulation of clinical	trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice. Analogies with and extensions to other diseases in the generic ISM context. The case of glioma (including glioblastoma multiforme.)	TEXTBOOK - Chapter 16 TEXTBOOK - Chapter 17
5.	formulation of clinical tumour invasion	trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice. Analogies with and extensions to other diseases in the generic <i>ISM</i> context. The case of glioma (including glioblastoma multiforme.) Non invasive estimation of	TEXTBOOK - Chapter 17
5.	formulation of clinical	trials as sources of multiscale data for the clinical adaptation and validation of Oncosimulators. Biobanks and related technologies. Clinical prerequisites for the translation of multiscale models and Oncosimulators into clinical practice. Analogies with and extensions to other diseases in the generic ISM context. The case of glioma (including glioblastoma multiforme.)	

	equation of diffusion-	description of parameter	
	reaction with	estimation. Anisotropic	
	pertinent boundary	tumour cell movement	
	conditions.	within inhomogeneous brain	
	Related	tissue.	
	mathematical and	Estimation of tumour	
	computational	necrosis and regrowth using	
	problems in the	pertinent mathematical	
	, generic <i>IS</i> M.	parameters. Estimation of	
	0	the effect of the	
		microenvironment on glioma	
		growth by comparing MRI	
		and PET tomographic	
		images.	
		Analogies with and	
		extensions to other diseases	
		in the generic <i>ISM</i> context.	
6.	Numerical methods	Finite Difference – Time	PAPER_C
0.	for the solution of the	Domain (FDTD) techniques.	
	spatiotemporal	Application of the Crank-	detailed numerical treatment of the
	problem of tumour	Nicolson technique in	boundary conditions imposed by the
	invasion into normal	conjunction with the	skull on a diffusion–reaction model of glioma tumor growth. Clinical
		-	validation aspects," Applied
	tissues including an	conjugate gradient method for the numerical solution of	Mathematics and Computation
	explicit consideration		218(2012) pp. 8779-8799]
	of the boundary	the partial differential	
	conditions.	equation (PDE) of reaction-	PROCEEDINGS
	Related	diffusion during glioma	
	mathematical and	growth and infiltration into	
	computational	normal brain tissue.	
	problems in the	Numerical application of the	
	generic ISM.	boundary Neumann	
		conditions between skull and	
		intracranial tissues.	
		Exploitation of the results for	
		the patient individualized	
		radiation treatment	
		planning. Glioma	
		biomechanics using	
		numerical methods such as	
		the Finite Element Method	
		(FEM.)	
		Analogies with and	
		extensions to other diseases	
		in the generic ISM context.	
		_	
L	1	I	1

7.	Modelling and	Tumour- microenvironment	TEXTBOOK - Chapter 13
7.	simulation of	interaction. Partial	TEXTBOOK Chapter 15
	angiogenesis during	differential equation for the	PROCEEDINGS
	tumour growth.	description of angiogenesis.	
	Related	Blood flow and capillary	
	mathematical and	blood vessel network	
	computational	formation. Adaptation and	
	problems in the	restructuring of the capillary	
	generic <i>ISM</i> .	vessel network. Numerical	
	generie ioivi.	solution methods.	
		Computational exploration	
		of the angiogenesis	
		phenomenon and the basic	
		factors they affect its course.	
		Analogies with and	
		extensions to other diseases	
		in the generic <i>IS</i> M context.	
8.	Modelling and	Molecular simulations at the	TEXTBOOK - Chapter 2
	simulation of	atomistic level based on the	
	molecular	Newton's and Coulomb's	PROCEEDINGS
	interactions,	laws and quantum	
	molecular pathways,	mechanics principles.	
	molecular signal	Molecular binding models.	
	transmission and the	Drug molecule – protein	
	resulting behaviour of	interaction simulations in	
	the cancer cell.	oncology. Molecular	
	Related	dynamics methods for the	
	mathematical and	characterization of the	
	computational	structural properties of	
	problems in the	mutated gene products. Use	
	generic ISM.	of ordinary differential	
		equations for the description	
		of oncogenetic and general	
		networks and pathways of	
		molecular signalling and	
		interaction. Resulting	
		behaviour of the tumour	
		cell.	
		Analogies with and	
		extensions to other diseases	
		in the generic ISM context.	